GlassScriptPhysician profile
David C Owens
NPI 1780624304
$3,534.68
in general payments reported to CMS, 2019-2025
38 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $55.80 · 2021: $256 · 2022: $380 · 2023: $230 · 2024: $1,382 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.61 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $538.32 | 2019-2025 | Erleada, Akeega |
| Teleflex LLC | $532.99 | 2021-2023 | Urolift |
| Astellas Pharma US INC | $454.49 | 2019-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $240.78 | 2024-2025 | Gemtesa, Orgovyx |
| Immunitybio, INC. | $152.53 | 2024 | |
| Endo USA, INC. | $133.06 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $121.73 | 2025 | |
| Urovant Sciences INC | $114.28 | 2022 | |
| Pfizer INC. | $113.21 | 2024-2025 | |
| Procept Biorobotics Corporation | $103.26 | 2024 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $102.13 | 2024-2025 | Provenge |
| Boston Scientific Corporation | $75.00 | 2023 | |
| Endo Pharmaceuticals INC. | $74.79 | 2019-2024 | Xiaflex |
| Olympus America INC. | $70.85 | 2024 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $61.81 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $61.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $58.00 | 2024-2025 | |
| Tolmar, INC. | $42.14 | 2024-2025 | Jatenzo, Eligard |
| C. R. Bard, INC. & Subsidiaries | $39.20 | 2019 | |
| Karl Storz Endoscopy-America | $39.11 | 2022 | |
| Accord Healthcare, INC. | $38.51 | 2022-2024 | |
| Abc Home Medical Supply, INC. | $36.31 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $35.55 | 2024-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $33.62 | 2024 | |
| Steris Corporation | $32.90 | 2024 | |
| Myriad Genetic Laboratories, INC. | $30.26 | 2024 | Prolaris |
| Antares Pharma, INC. | $28.44 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $21.78 | 2025 | Keytruda Qlex, Keytruda |
| Medtronic, INC. | $21.38 | 2024 | Interstim |
| 180 Medical, INC. | $19.91 | 2024 | |
| Hollister Incorporated | $18.57 | 2024 | |
| Telix Pharmaceuticals | $17.43 | 2024 | Illuccix |
| Azurity Pharmaceuticals, INC. | $15.43 | 2025 | Azmiro |
| Dentsply Ih INC. | $15.28 | 2020 | |
| Bard Access Systems, INC. | $13.65 | 2019 | |
| Neotract INC. | $13.41 | 2020 | |
| Acerus Pharmaceuticals Corporation | $13.18 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.